CN113116791A - 沉默调节蛋白1活化剂和用于活化沉默调节蛋白1的皮肤化妆品 - Google Patents
沉默调节蛋白1活化剂和用于活化沉默调节蛋白1的皮肤化妆品 Download PDFInfo
- Publication number
- CN113116791A CN113116791A CN202110036612.6A CN202110036612A CN113116791A CN 113116791 A CN113116791 A CN 113116791A CN 202110036612 A CN202110036612 A CN 202110036612A CN 113116791 A CN113116791 A CN 113116791A
- Authority
- CN
- China
- Prior art keywords
- sirtuin
- extract
- banana
- echinacea
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010041191 Sirtuin 1 Proteins 0.000 title claims abstract description 80
- 239000012190 activator Substances 0.000 title claims abstract description 37
- 239000002537 cosmetic Substances 0.000 title claims abstract description 25
- 230000003213 activating effect Effects 0.000 title claims abstract description 22
- 102000000344 Sirtuin 1 Human genes 0.000 title claims abstract 8
- 239000000284 extract Substances 0.000 claims abstract description 74
- 241000234295 Musa Species 0.000 claims abstract description 67
- 235000014134 echinacea Nutrition 0.000 claims abstract description 60
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract description 55
- 244000133098 Echinacea angustifolia Species 0.000 claims abstract description 46
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 240000004530 Echinacea purpurea Species 0.000 claims description 14
- 230000004913 activation Effects 0.000 claims description 11
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims description 10
- 229940002010 banana extract Drugs 0.000 claims description 6
- 235000021015 bananas Nutrition 0.000 claims description 5
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 61
- 239000000203 mixture Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000000605 extraction Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 238000002156 mixing Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 235000012149 noodles Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 102000011990 Sirtuin Human genes 0.000 description 5
- 108050002485 Sirtuin Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 230000032677 cell aging Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- -1 aliphatic alcohols Chemical class 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000003805 Musa ABB Group Nutrition 0.000 description 2
- 235000015266 Plantago major Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 208000015606 cardiovascular system disease Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001506951 Alpinia nigra Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
- 244000291473 Musa acuminata Species 0.000 description 1
- 241000234615 Musaceae Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000973598 Oxyjulis californica Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 101700026522 SMAD7 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N Trimethylene glycol Natural products OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010091356 Tumor Protein p73 Proteins 0.000 description 1
- 102000018252 Tumor Protein p73 Human genes 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 201000011032 Werner Syndrome Diseases 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940045811 echinacea purpurea extract Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000035777 life prolongation Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000015090 marinades Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
Abstract
提供一种沉默调节蛋白1活化剂,该沉默调节蛋白1活化剂包括具有高安全性的天然提取物作为活性成分,以及用于活化沉默调节蛋白1的皮肤化妆品。紫锥菊和/或香蕉的提取物被用作本发明的沉默调节蛋白1活化剂的活性成分。此外,将本发明的用于活化沉默调节蛋白1的皮肤化妆品与紫锥菊和/或香蕉的提取物混合。
Description
技术领域
本发明涉及包含作为活性成分的紫锥菊(echinacea)和/或香蕉的提取物的沉默调节蛋白1(sirtuin 1)活化剂以及用于活化沉默调节蛋白1的皮肤化妆品。
背景技术
在衰老控制的研究中,已经发现将卡路里限制到一定程度,以使古细菌、酵母、线虫和人类不会陷入低营养状态,赋予了抗衰老和长寿效果。Sir2已被确定为参与这些效果的分子之一。在哺乳动物同源物中,有七个沉默调节蛋白家族成员。其中,与Sir2的结构和功能最相似的沉默调节蛋白1引起了注意。
沉默调节蛋白1具有NAD依赖性去乙酰基酶活性和ADP核糖基转移酶活性,并且在生物体内起重要作用。例如,在表达高水平沉默调节蛋白1的小鼠的情况下,已经认识到身体能力的增强、增殖期的延长以及糖代谢、胆固醇代谢和脂肪代谢的改善。此外,已经观察到甚至尽管高脂饮食也改善了葡萄糖耐受并抑制了脂肪肝。换句话说,认为沉默调节蛋白1的活化对于预防或治疗代谢疾病或从代谢疾病中恢复是有用的(非专利文献1)。
此外,沉默调节蛋白1的活化使转录因子NF-κB(核因子-κB)的p65亚基去乙酰化,且因此NF-κB活性减弱,从而明显抑制炎症。认为该抗炎作用能够用于预防或治疗炎性疾病或从炎性疾病中恢复(非专利文献1)。此外,在小鼠中,可以看到,通过阻断NF-κB基因可以增强皮肤的增殖完整性,并且认为沉默调节蛋白1的活化有助于增强皮肤的增殖完整性(非专利文献2)。
沉默调节蛋白1使FOXO、p53、p73、Ku70和Smad7去乙酰化,且因此诱导了抗氧化应激并抑制细胞死亡。认为其表型诱导有助于实现抗衰老和延长寿命的作用(非专利文献1)。
细胞衰老变性是由暴露于外源应激(诸如紫外线)引起的。细胞衰老变性是一种细胞周期被永久停止的现象。已经发现,沉默调节蛋白1调节TERT(端粒逆转录酶)的表达,因此组蛋白被去乙酰化,从而保持了端粒的稳定性,而修复蛋白(如WRN蛋白(Werner综合征蛋白))被去乙酰化,从而促进了DNA的修复,由此保持了基因组的稳定性以及这些功能抑制了细胞衰老变性(非专利文献3)。
如上所述,已发现沉默调节蛋白1具有多种功能,例如代谢疾病恢复作用、炎症疾病恢复作用、细胞衰老变性抑制作用、糖尿病恢复作用、心血管保护作用、肾脏疾病恢复作用和神经保护作用。因此,沉默调节蛋白1的活化被认为可用于预防或治疗各种疾病,或从各种疾病中恢复,例如代谢性疾病、炎性疾病、细胞衰老变性、糖尿病、心血管疾病、肾脏疾病和神经系统疾病。
作为用于活化沉默调节蛋白1的材料,已知在红葡萄皮中含有大量白藜芦醇。近来,也已经报道了如专利文献1中所述的源自黑姜提取物的沉默调节蛋白活化剂(专利文献1)。
【现有技术文献】
【专利文献】
(专利文献):日本早期公开专利申请第2018-199680号
【非专利文献】
(非专利文献1):Chemistry and Biology,2009,第47卷,第8期,第531-537页
(非专利文献2):Aging cell,2010,9,第285-290页
(非专利文献3):BMB Reports,2019,52(1),第24-34页。
发明内容
因此,考虑到现有技术中存在的上述问题做出了本发明,并且本发明的目的是从具有高安全性的天然提取物中找到具有活化沉默调节蛋白1的作用的材料,并提供一种包含作为活性成分的该材料的沉默调节蛋白1活化剂和一种用于活化沉默调节蛋白1的皮肤化妆品。
为了实现上述目的,本发明的沉默调节蛋白1活化剂包含紫锥菊和/或香蕉的提取物作为活性成分。此外,本发明的用于活化沉默调节蛋白1的皮肤化妆品混合有紫锥菊和/或香蕉的提取物。
本发明的沉默调节蛋白1活化剂包含是天然产物的紫锥菊和/或香蕉的提取物作为活性成分。因此,可以提供不仅具有优异活性而且具有高安全性的沉默调节蛋白1活化剂。
此外,可以提供用于活化沉默调节蛋白1的皮肤化妆品,其混合有紫锥菊和/或香蕉的提取物,从而具有优异的活性和高安全性。
具体实施方式
在下文中,将描述本发明的实施方式。
[沉默调节蛋白1活化剂]
本实施方式的沉默调节蛋白1活化剂包含作为活性成分的紫锥菊(学名:紫锥菊Echinacea purpurea)和/或香蕉(学名:香蕉Musa Spp.)的提取物。
在本实施方式中的“提取物”的实例包括从用作提取原料的紫锥菊(学名:紫锥菊Echinacea purpurea)或香蕉(学名:香蕉Musa Spp.)获得的提取液、提取液的稀释液或浓缩液、通过干燥提取液获得的干燥物质以及其粗纯化的物质或纯化物质。
紫锥菊是菊科的紫锥菊属的多年生植物,分布于北美等地。在日本全国各地也栽培有用于观赏目的的紫锥菊,且可以容易从这些地区获得。可用作提取原料的紫锥菊的组成部分包括地上部分诸如叶部分、茎部分、花部分,地下部分诸如根部分、种子,整株植物,或这些部分的混合物,但优选根部分。
香蕉(学名:香蕉Musa spp.)是属于芭蕉科的芭蕉属的植物中具有可食用的果实的植物,并且在东南亚等地栽培,并且可以容易地从这些地区获得。尽管没有特别限定作为本发明中可以用作提取原料的香蕉的栽培品种,但是可以合适地使用高秆香芽蕉、台湾香蕉、大矮蕉(Grande Naine)、红皮蕉(morado)、Shimabanana蕉、Senorita(猴香蕉MonkeyBanana)、Lakata蕉和大蕉(plantain)。香蕉的可用作提取原料的组成部分包括例如地上部分例如叶部分、假茎部分、花部分、果实部分、果皮部分,地下部分例如茎部分、根部分,或这些部分的混合物,但优选叶部分。
用于提取的原料可以干燥、静置或使用破碎机粉碎,并且可以使用提取溶剂提取,从而获得上述植物的提取物。干燥可以使用阳光进行,或者可以使用通常使用的干燥机进行。此外,可以使用非极性提取溶剂例如己烷进行诸如脱脂的预处理,从而有效地实现利用极性溶剂的提取处理。
优选使用极性溶剂作为提取溶剂。其实例可以包括水和亲水性有机溶剂,其优选在室温下或在低于溶剂沸点的温度下单独使用或以其两种或更多种的组合使用。
可以用作提取溶剂的水的实例包括纯净水、自来水、井水、矿泉水、含有矿物质的水、温泉水,可使用的水以及经过各种处理的淡水。应用于水的处理的实例包括净化、加热、灭菌、过滤、离子交换、渗透压力调节和缓冲。因此,在本实施方式中可以用作提取溶剂的水的实例包括纯净水、热液水、离子交换水、生理盐水、磷酸盐缓冲液和磷酸盐缓冲生理盐水。
可用作提取溶剂的亲水性有机溶剂的实例可以包括具有1-5个碳原子的低级脂族醇,例如甲醇、乙醇、丙醇和异丙醇;低级脂族酮,例如丙酮和甲乙酮;和具有2至5个碳原子的多元醇,例如1,3-丁二醇、丙二醇和甘油。
当使用两种或更多种极性溶剂的混合溶液作为提取溶剂时,其混合比可以适当地调节。例如,当使用水和低级脂族醇的混合溶液作为提取溶剂时,水和低级脂族醇的混合比优选为9:1至2:8(体积比)。此外,当使用水与低级脂族酮的混合溶液时,水与低级脂族酮的混合比优选为9:1至2:8(体积比)。此外,当使用水和多元醇的混合溶液时,水和多元醇的混合比优选为9:1至1:9(体积比),且更优选7:3至2:8(体积比)。
提取处理没有特别限制,只要可以将用于提取的原料中所含的可溶性成分洗脱在提取溶剂中即可,并且可以根据典型方法进行。例如,提取原料可以浸入到是提取原料量的1.5至300倍(质量比)的量的提取溶剂中,并且可溶性成分可以在室温下或者通过加热回流,然后过滤以除去提取残余物来提取,从而获得提取液。从得到的提取液中蒸馏溶剂得到糊状的浓缩物,将浓缩物进一步干燥,从而得到干燥产物。
可以例如使用活性炭处理、吸附树脂处理或离子交换树脂处理来进行纯化。所获得的提取液可以不经进一步处理而用作沉默调节蛋白1活化剂的活性成分,但是浓缩物或干燥产物的形式易于使用。
由于如上所述获得的紫锥菊和香蕉提取物具有沉默调节蛋白1活化作用,因此该提取物可以用作沉默调节蛋白1活化剂的活性成分。
本实施方式的沉默调节蛋白1活化剂可以用于药物、医疗用品、准药物、化妆品以及食品等广泛的用途。
本实施方式的沉默调节蛋白1活化剂可以仅包含紫锥菊或香蕉的提取物,也可以通过配制紫锥菊或香蕉的提取物而得到。
使用糊精或环糊精的药学上可接受的载体和根据典型方法的任何其他辅助剂,可以将本实施方式的沉默调节蛋白1活化剂配制成粉末相、颗粒相、片剂相、液相等各种制剂中的任一种。辅助剂的实例可包括赋形剂、粘合剂、崩解剂、润滑剂、稳定剂和矫味剂。沉默调节蛋白1活化剂可以与其他组合物(如用于皮肤的外部制剂和口服组合物等)组合使用,并且可以用作软膏、外用液体药物或薄片剂。
当配制本实施方式的沉默调节蛋白1活化剂时,紫锥菊或香蕉提取物的含量没有特别限制,并且可以根据目的适当设定。
同时,如果需要的话,本实施方式的沉默调节蛋白1活化剂可以通过将具有沉默调节蛋白1活化作用的其他天然提取物与紫锥菊或香蕉的提取物混合而用作活性成分。
将本实施方式的沉默调节蛋白1活化剂施用至患者的方法的示例可以包括透皮施用和口服施用,但是可以根据疾病的种类适当选择适合于预防和治疗的方法。此外,本实施方式的沉默调节蛋白1活化剂的剂量可以根据疾病的种类或严重程度、患者之间的个体差异、施用方法和施用时期适当地增加或减少。
本实施方式的沉默调节蛋白1活化剂可以用于预防或治疗诸如代谢性疾病、炎性疾病、细胞衰老变性、糖尿病、心血管疾病、肾脏疾病和神经系统疾病的各种疾病或从这些疾病中恢复的目的,以及进一步用于与涉及沉默调节蛋白1的各种现象有关的目的,例如由于紫锥菊或香蕉提取物的沉默调节蛋白1活化作用而产生的抗衰老或延长寿命的作用。但是,本实施方式的沉默调节蛋白1活化剂除了上述用途以外,还可以用于对发挥沉默调节蛋白1活化作用具有重要意义的所有目的。
紫锥菊和香蕉的提取物具有沉默调节蛋白1活化作用,并且在施用于皮肤时也具有出色的可用性或安全性,因此,这些提取物非常适合用作混合时皮肤外用制剂中的成分。在皮肤外用剂的情况下,可以在不进行处理的情况下将紫锥菊或香蕉的提取物混合其内,或者可以将由紫锥菊或香蕉的提取物配制的沉默调节蛋白1活化剂混合其内。可以将紫锥菊或香蕉的提取物或由紫锥菊或香蕉的提取物配制的沉默调节蛋白1活化剂混合到皮肤外用剂中,从而赋予其沉默调节蛋白1活化作用。
皮肤外用制剂的类型不受限制,其实例包括各种各样的产品,例如稍后将描述的皮肤化妆品,以及在皮肤上使用的准药物和药品以及医疗用品。
此外,由于本实施方式的紫锥菊和香蕉的提取物具有优异的沉默调节蛋白1活化作用,因此该提取物可以适合用作研究其作用机理的试剂。
另外,本实施方式的沉默调节蛋白1活化剂适用于人,但只要表现出活性,也可以适用于人以外的动物。
[用于活化沉默调节蛋白1的皮肤化妆品]
由于根据上述实施方式的紫锥菊和香蕉的提取物具有优异的沉默调节蛋白1活化作用,因此该提取物适合与皮肤化妆品混合。在这种情况下,可以将用于活化沉默调节蛋白1的成分的紫锥菊或香蕉的提取物混合而无需进行任何处理,或者可以混合由紫锥菊或香蕉的提取物配制的沉默调节蛋白1活化剂。
对可以与紫锥菊或香蕉的提取物混合的皮肤化妆品的种类没有特别的限制,其实例可以包括软膏、乳膏、乳状洗剂、洗剂、面膜(pack)和粉底液。
当将紫锥菊或香蕉的提取物与皮肤化妆品混合时,紫锥菊或香蕉的提取物混合在其内的量可以根据皮肤化妆品的类型适当地调节。然而,合适的混合比例为0.0001至10质量%(以固体含量计),并且特别合适的混合比例为0.001至1质量%(以固体含量计)。
只要不阻碍紫锥菊和香蕉提取物的沉默调节蛋白1活化作用,本实施方式的皮肤化妆品可以与主剂、助剂或其他成分组合使用,其他成分例如制造典型的皮肤化妆品中使用的收敛剂、杀菌剂/抗微生物剂、紫外线吸收剂、保湿剂、细胞增效剂、消炎剂/抗过敏药、抗氧化剂/活性氧去除剂、油脂、蜡、烃、脂肪酸、醇、酯、表面活性剂和风味剂。通过以这种方式一起使用它们,皮肤化妆品成为更普通的产品,并且与它们组合使用的上述成分之间的协同作用导致使用效果优于通常预期的效果。
该皮肤化妆品具有高安全性,并且可以用于预防或治疗诸如代谢疾病、炎性疾病、细胞衰老变性、糖尿病、心血管疾病、肾脏疾病和神经系统疾病等各种疾病或从这些疾病中恢复的目的,以及进一步涉及沉默调节蛋白1的各种现象的目的,例如由于其对沉默调节蛋白1的活化作用而具有抗衰老和延长寿命的作用。
[用于活化沉默调节蛋白1的口服组合物]
紫锥菊和香蕉的提取物具有沉默调节蛋白1活化作用,并且具有极好的安全性,因此该提取物适合与口服组合物混合。在口服组合物的情况下,可以不进行任何处理就混合紫锥菊或香蕉的提取物,或者可以混合由紫锥菊或香蕉的提取物配制的沉默调节蛋白1活化剂。紫锥菊或香蕉的提取物或由紫锥菊或香蕉的提取物配制的沉默调节蛋白1活化剂可以混合以使口服组合物具有沉默调节蛋白1活化作用。
口服组合物是指在正常的社会生活中通过口服或消化道施用不会危害人体健康的产品。根据行政分类,食品不限于食品、药物和医疗用品以及准药物的类别。因此,在本实施方式中,术语“口服组合物”包括口服的多种食品,例如普通食品、保健食品、保健功能食品(特定健康食品、营养功能食品、具有功能要求的食物)、准药物和药物以及医疗用品。
当将紫锥菊或香蕉的提取物与口服组合物混合时,其活性成分的混合量可以根据使用目的、症状和性别而适当地变化。然而,考虑到要添加的口服组合物的一般摄入量,优选每位成年人的提取物的摄入量为每天约1至1000mg。此外,当要添加的口服组合物是粒状、片状或胶囊型口服组合物时,紫锥菊或香蕉的提取物的添加量通常为基于要添加的口服组合物的量的0.1至100质量%,并且优选为5至100质量%。
本实施方式的口服组合物可以与不妨碍紫锥菊或香蕉提取物的活性的任何口服组合物混合,或者可以是包括作为主要成分的紫锥菊或香蕉的提取物的营养补品。
当制造本实施方式的口服组合物时,可以向其中加入例如任意的辅助剂,如,诸如糊精或淀粉的糖,诸如明胶、大豆蛋白或玉米蛋白的蛋白质,诸如丙氨酸、谷氨酰胺或异亮氨酸的氨基酸,多糖如纤维素或阿拉伯树胶,以及脂和油,如大豆油或中链脂肪酸甘油三酸酯,从而获得预定形式的口服组合物。
与紫锥菊或香蕉的提取物混合的口服组合物没有特别限制。然而,其具体示例可以包括饮料,例如软饮料、碳酸饮料、营养饮料、果汁饮料和乳酸饮料(包括饮料的浓缩粗制液体和用于调节的粉末);以及冰糕例如冰淇淋、冰沙和冰片;面条,诸如荞麦面、乌冬面、玻璃纸面(cellophane noodle)、饺子皮、小米卷、中式面、方便面等;甜食诸如韩国硬太妃糖、口香糖、糖果、口香糖、巧克力、正果(Jeongkwa)、点心、饼干、果冻、果酱、奶油和烤制饼干;加工的海鲜和牲畜食品,例如鱼糕、火腿和香肠;乳制品,例如加工乳和发酵乳;脂和油和以油脂为基础的加工食品,例如色拉油、煎炸油、人造黄油、蛋黄酱、起酥油、生奶油和调料;调味料例如酱汁和腌泡汁;汤、炖菜、色拉、配菜、咸菜、各种其他健康和营养补品、片剂、胶囊和健康饮料。将紫锥菊或香蕉的提取物与口服组合物混合时,也可以使用常用的辅助原料或添加剂。
[实施例]
在下文中,将参考实施例具体描述本发明,但是本发明不限于以下实施例。
[实施例1]制备紫锥菊的根部分的提取液
将4kg 50%BG(1,3-丁二醇,Hisugacane BG,由Kokyu Alcohol Kogyo Co.,Ltd制造)与20g紫锥菊的根部分的干燥产物混合并浸没持续7天。使用ADVANTEC定性滤纸(No.2,由Toyo Roshi Kaisha,Ltd.制造)和膜(0.45μm)进行过滤,并获得紫锥菊的根部分的提取物(固体含量:3.19质量%)作为滤出液。
[实施例2]制备香蕉的叶部分的提取液
将20g香蕉(Musa Spp.,Shima Banana)的干叶与4kg 50%BG(1,3-丁二醇,Hisugacane BG,由Kokyu Alcohol Kogyo Co.,Ltd制造)混合,然后浸入其中持续七天。使用ADVANTEC定性滤纸(No.2,由Toyo Roshi Kaisha,Ltd.制造)和膜(0.45μm)进行过滤,并获得香蕉叶部分的提取物(固体含量:0.33质量%)作为滤出液。
[比较实施例1]制备NMN(烟碱酰胺单核苷酸)溶液
NMN(烟碱酰胺单核苷酸)购自东京化学工业株式会社(Tokyo Chemical IndustryCo.,Ltd.),并且使用磷酸盐缓冲溶液(PBS(1),由Sigma-Aldrich Co.LLC.)制造)制备0.43%的NMN溶液。
[测试实施例1]沉默调节蛋白1基因的表达测试
对实施例1的修剪的紫锥菊的根部分的提取液、实施例2的香蕉的叶部分的提取液以及比较实施例1的NMN溶液进行沉默调节蛋白1基因的表达测试。
使用含有10%胎牛血清(FBS,由Thermo Fisher Scientific Inc.制造)的Dulbecco的改进的Eagle培养基(DMEM,由Thermo Fisher Scientific Inc.制造)在37℃下于5%CO2下预培养人类新生儿包皮来源的成纤维细胞(继代数为3),并通过用0.25%胰蛋白酶(由Sigma-Aldrich Co.LLC.制造)处理来收集细胞。回收的细胞用10%FBS/DMEM稀释至3×104细胞/ml的浓度,然后在50个烧瓶中每个以5mL的量播种以培养细胞(由SumitomoBakelite Co.,Ltd.制造),然后培养2小时。之后,向其加入1.35μL的实施例1(样品浓度为8.6μg/mL)、13μL的实施例2(样品浓度为8.6μg/mL)、10μL的比较实施例1(样品浓度8.6μg/mL),然后培养三天。
确认无细胞毒性后,除去培养基,用磷酸盐缓冲液(PBS(1),Sigma-AldrichCo.LLC.制造)洗涤和向其中加入1mL的1%SDS溶液(由NIPPON GENE CO.,LTD.制造),以回收细胞。使用涡旋充分搅拌细胞悬液后,取样180μL细胞悬液。向其中加入1μL的1%KOH(由NACALAI TESQUE,INC.制造)和20μL的蛋白酶K溶液(由Thermo FisherScientific Inc.制造),然后搅拌,然后在37℃下温育15分钟。温育后,将100μL的RNAClean XP(由Beckman Coulter,Inc.制造)加入其中,搅拌,并在磁力架上放置5分钟。去除上清液,使用85%乙醇洗涤两次,干燥10分钟,并且向其中添加30μL的无核酸酶的水(由ThermoFisher Scientific Inc.制造)。将所得物质在磁力架上放置5分钟,并使用RNA溶液进行上清液处理。
进行制备,以使在0℃下,在200μL的PCR管(由Bio-Rad LaboratoriesInc.制造,透明,圆顶盖)中,Super ScriptTM IV VILOTM Master Mix(由Thermo Fisher ScientificInc.制造)与无核酸酶的水之比为1:2.5,然后使用涡旋搅拌并以14.0μL的量分配到另一个PCR管中。制备NRT样品,以使Super ScriptTM IV VILOTM无RT对照(由Thermo FisherScientific Inc.制造)与无核酸酶的水之比为1:2.5,然后分配。将如上所述获得的RNA溶液以6.0μL的量添加至其中,然后使用热循环仪(由Bio-Rad Laboratories Inc.制造,T100TM热循环仪)在25℃温育10分钟,50℃温育10分钟,然后在85℃温育5分钟,从而获得cDNA样品和NRT样品。
进行制备,以使Taqman(R)基因表达测定(ACTB Hs99999903_m1或SIRT1Hs01009006_m1,由Thermo Fisher Scientific Inc.制造)、TaqPathTM qPCR Master Mix,CG(由Thermo Fisher Scientific Inc.制造)和无核酸酶的水之比为1:10:5。将得到的样品置于无核酸酶的管中,用涡旋搅拌,然后离心。将所得物质以16.0μL的量分配到PCR管(由Bio-Rad Laboratories Inc.制造,白色,平盖)中,并分别以4.0μL的量添加cDNA样品和NRT样品,然后移液并使用涡旋进行搅拌,然后离心。
使用上述样品进行实时PCR(由Bio-Rad Laboratories Inc.制造,C1000TouchTM热循环仪)。PCR在25℃2分钟、95℃20秒,95℃3秒(1)和60℃30秒(2)(1→2 40个循环)的PCR条件下进行。
结果列于表1。
[表1]
Cq:扩增曲线与临界值交叉的循环数
β-肌动蛋白:内隐控制
△Cq:沉默调节蛋白Cq-β-肌动蛋白Cq
比例*1000:2(-△Cq)×1000
当样品浓度为8.6μg/mL时,实施例1中的沉默调节蛋白1基因的表达被确认为是未处理的对照的2.26倍,实施例2中的是未处理的对照的2.19倍,但在比较实施例1中,在相同浓度下未观察到沉默调节蛋白1基因的表达。根据以上结果,发现在实施例1和2中,沉默调节蛋白1基因的活性强于比较实施例1。
[配合实施例1]
使用典型的方法根据以下组成制造乳状洗剂。
[配合实施例2]
使用典型的方法制造具有以下组成的乳膏。
香蕉提取物 0.01g
苦参提取物 0.1g
姜黄提取物 0.1g
液体石蜡 5.0g
白蜂蜡 4.0g
角鲨烯 10.0g
鲸蜡醇 3.0g
羊毛脂 2.0g
硬脂酸 1.0g
聚氧乙烯脱水山梨糖醇油酸酯(20E.0.) 1.5g
单硬脂酸甘油酯 3.0g
油溶性甘草提取物 0.1g
1,3-丁二醇 6.0g
对羟基苯甲酸甲酯 1.5g
风味剂 0.1g
纯净水 余量(总量为100g)
[配合实施例3]
使用典型的方法制造具有以下组成的化妆液。
紫锥菊提取物 0.01g
香蕉提取物 0.01g
抗坏血酸2-葡萄糖苷 0.1g
洋甘菊提取物 0.1g
胡萝卜提取物 0.1g
黄原胶 0.3g
羟乙基纤维素 0.1g
羧乙烯基聚合物 0.1g
1,3-丁二醇 4.0g
甘草酸二钾 0.1g
甘油 2.0g
氢氧化钾 0.25g
风味剂 0.01g
防腐剂(对羟基苯甲酸甲酯) 0.15g
乙醇 2.0g
纯净水 余量(总量为100g)
本发明的沉默调节蛋白活化剂可以极大地有助于实现预防或治疗各种疾病或从各种疾病中恢复,例如代谢性疾病、炎性疾病、细胞衰老变性、糖尿病、心血管疾病、肾脏疾病和神经系统疾病,以及实现抗衰老和延长寿命的作用。
Claims (10)
1.一种沉默调节蛋白1活化剂,包含:
作为活性成分的紫锥菊和/或香蕉的提取物。
2.根据权利要求1所述的活化剂,所述紫锥菊和/或香蕉的提取物使沉默调节蛋白1基因的活化增强约2倍或更多倍。
3.根据权利要求1所述的活化剂,活化沉默调节蛋白1基因所需的所述紫锥菊和/或香蕉的提取物的浓度低于活化所述沉默调节蛋白1基因所需的NMN(烟碱酰胺单核苷酸)溶液的浓度。
4.根据权利要求1所述的活化剂,所述紫锥菊的提取物是从紫锥菊的根部分提取的提取物。
5.根据权利要求1所述的活化剂,所述香蕉的提取物是从香蕉的叶部分提取的提取物。
6.一种用于活化沉默调节蛋白1的皮肤化妆品,其混合有紫锥菊和/或香蕉的提取物。
7.根据权利要求6所述的皮肤化妆品,所述紫锥菊和/或香蕉的提取物使沉默调节蛋白1基因的活化增强约2倍或更多倍。
8.根据权利要求6所述的皮肤化妆品,活化沉默调节蛋白1基因所需的所述紫锥菊和/或香蕉的提取物的浓度低于活化所述沉默调节蛋白1基因所需的NMN(烟碱酰胺单核苷酸)溶液的浓度。
9.根据权利要求6所述的皮肤化妆品,所述紫锥菊的提取物是从紫锥菊的根部分提取的提取物。
10.根据权利要求6所述的皮肤化妆品,所述香蕉的提取物是从香蕉的叶部分提取的提取物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020004187A JP2021109861A (ja) | 2020-01-15 | 2020-01-15 | サーチュイン1活性化剤及びサーチュイン1活性化用皮膚化粧料 |
JP2020-004187 | 2020-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113116791A true CN113116791A (zh) | 2021-07-16 |
Family
ID=76763850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110036612.6A Pending CN113116791A (zh) | 2020-01-15 | 2021-01-12 | 沉默调节蛋白1活化剂和用于活化沉默调节蛋白1的皮肤化妆品 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210212928A1 (zh) |
JP (1) | JP2021109861A (zh) |
KR (1) | KR20210092126A (zh) |
CN (1) | CN113116791A (zh) |
SG (1) | SG10202012517YA (zh) |
TW (1) | TW202128130A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102590533B1 (ko) | 2022-05-13 | 2023-10-17 | 주식회사 키프로젠 | 단백질 전달 서열 융합 시르투인6 생산방법 및 이를 함유하는 화장료 조성물 및 약학 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125571B2 (en) * | 2003-11-25 | 2006-10-24 | D & E Pharmaceuticals, Inc. | Herbal formulation |
WO2013100111A1 (ja) | 2011-12-27 | 2013-07-04 | 油田 正樹 | サーチュイン活性化剤 |
EP3342395A4 (en) * | 2015-08-27 | 2019-02-20 | LG Household & Health Care Ltd. | SURFACE MODIFICATION COMPOSITION |
KR20180104960A (ko) * | 2017-03-14 | 2018-09-27 | 코스맥스 주식회사 | 바나나, 체리 및 호두의 혼합 추출물을 포함하는 피부 노화 방지 또는 개선용 조성물 |
-
2020
- 2020-01-15 JP JP2020004187A patent/JP2021109861A/ja active Pending
- 2020-12-14 KR KR1020200174114A patent/KR20210092126A/ko unknown
- 2020-12-14 SG SG10202012517YA patent/SG10202012517YA/en unknown
- 2020-12-18 TW TW109145026A patent/TW202128130A/zh unknown
-
2021
- 2021-01-12 CN CN202110036612.6A patent/CN113116791A/zh active Pending
- 2021-01-14 US US17/149,684 patent/US20210212928A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG10202012517YA (en) | 2021-08-30 |
KR20210092126A (ko) | 2021-07-23 |
TW202128130A (zh) | 2021-08-01 |
US20210212928A1 (en) | 2021-07-15 |
JP2021109861A (ja) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhao et al. | Acute toxicity and anti-fatigue activity of polysaccharide-rich extract from corn silk | |
Farag et al. | Valorization and extraction optimization of Prunus seeds for food and functional food applications: A review with further perspectives | |
Syabana et al. | Antidiabetic activity screening and nmr profile of vegetable and spices commonly consumed in Indonesia | |
JP2008163014A (ja) | 11βHSD1阻害剤及びその用途 | |
JP2010095529A (ja) | 脂質代謝改善用組成物 | |
JP2019163343A (ja) | グルコース吸収抑制剤 | |
CN114796295A (zh) | 包含人参提取物的用于促进肌肉分化及预防肌肉损伤的组合物、食品组合物及药学组合物 | |
CN113116791A (zh) | 沉默调节蛋白1活化剂和用于活化沉默调节蛋白1的皮肤化妆品 | |
JP7229513B2 (ja) | 脳の機能改善剤および脳の機能改善用飲食品 | |
JP2022111283A (ja) | 新規コラーゲン再利用促進作用剤 | |
JP2010037255A (ja) | 視機能低下予防又は改善剤 | |
KR102573074B1 (ko) | 시르투인1 활성화제 및 시르투인1 활성화용 피부 화장료 | |
JP2018168144A (ja) | リパーゼ阻害剤、及びその利用 | |
KR101525877B1 (ko) | 피부 주름 개선 및 피부 노화 방지를 위한 조성물 | |
KR101808808B1 (ko) | 벌나무 및 후박나무 추출물을 함유하는 당뇨병 또는 당뇨합병증 예방 및 치료용 조성물 | |
JP2017165686A (ja) | 肝機能改善剤 | |
KR100895500B1 (ko) | 호노키올을 유효성분으로 함유하는 지방간 질환의 예방 및치료용 조성물 | |
JP7300121B2 (ja) | 抗糖化用組成物、及び抗糖化用組成物の製造方法 | |
JP7095872B2 (ja) | インターロイキン-33産生抑制剤並びにインターロイキン-33の増加に関連するアレルギー疾患の予防、治療又は抑制用の医薬品、医薬部外品、化粧料及び飲食品組成物 | |
JPWO2007004570A1 (ja) | 持久力向上および/または抗疲労作用を有する組成物 | |
JP2003261457A (ja) | 皮膚化粧料及び美容用飲食品 | |
Spizzirri | Nutraceutics from Agri-food By-products | |
JP6629036B2 (ja) | 皮膚化粧料および飲食品 | |
JP2024082497A (ja) | 体脂肪低下剤及びスリミング剤 | |
KR20240032215A (ko) | 혼합생약재의 유산균 발효물을 유효성분으로 함유하는 항산화, 항염증 또는 면역조절용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40047433 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210716 |